摘要
【目的】探讨孟鲁司特钠对哮喘儿童肺功能及可溶性白介素2受体（sIL-2R）和肿瘤坏死因子-α（TNF-α）的影响。【方法】将20例6～14岁的轻中度哮喘儿童给予孟鲁司特钠治疗，每日1次，每次5mg．治疗共4周。分别在治疗前、治疗结束后进行肺功能检查。测定sIL-2R和TNF-α水平，并与健康对照组比较。【结果】哮喘患儿治疗后肺功能指标FEV1、FVC、PEF、V25和V50均比治疗前有明显改善（P〈0．01）。治疗前哮喘患儿血sIL-2R、TNF-α水平均高于正常儿童对照组（P〈0．05），治疗后血sIL，2R和TNF-α较治疗前明显降低（P〈0．05）。【结论】孟鲁司特钠可改善肺功能．降低血sIL-2R和TNF-α水平，在哮喘的抗炎治疗中起重要作用。
[Objective]To investigate the effect of montelukast on lung function and soluble interleukin 2 receptor （sIL-2R） and tumor necrosis factor-alpha（TNF-α） in asthmatic children. [Methods] Twenty children with mild to- moderate asthma were treated with montelukast with 5mg tablets for 1 month. Lung function parameters such as FEV1, FVC, PEF, V 25 and V50 were performed before and after treatment. Serum sIL-2R and TNF-α levels were determined in the control group and in asthmatic children before and after treatment. Twenty healthy children as control were enrolled in the study. [Results] After 1-month treatment, the mean FEV1, FVC, PEF, V 25 and VS0 were significantly increased （P〈0.01） after treatment with montelukast. The mean serum sIL-2R and TNF-α levels in patients were significantly higher before treatment than those after treatment（ P〈0.05） or in control subjects（ P〈0.05）. [Conclusion] Montelukast may improve lung function parameters and play an important role for anti in- flammatory effect by decreasing serum sIL2R and TNF-α levels.
出处
《医学临床研究》
CAS
2009年第4期588-590,共3页
Journal of Clinical Research
